Results 1 to 10 of about 20 (20)

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials

Parkinsonism and Related Disorders, 2019
Irène A Malaty, Joohi Jimenez-Shahed, Rajesh Pahwa   +2 more
exaly  

Dominant dark matter and a counter-rotating disc: MUSE view of the low-luminosity S0 galaxy NGC 5102

Monthly Notices of the Royal Astronomical Society, 2017
Michele Cappellari, Martin Mitzkus, Walcher C Jakob   +2 more
exaly  

Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial

Multiple Sclerosis Journal, 2019
Jeffrey Cohen
exaly  

A complete type patient with Behçet's disease associated with HLA‐B*5102

Acta Ophthalmologica, 1994
N Mizuki
exaly  

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)

JAMA Neurology, 2017
Caroline Tanner, , Kelly Lyons
exaly  

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia

Clinical Pharmacokinetics, 2018
, Rajesh Pahwa, Reed Johnson
exaly  

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102

Movement Disorders Clinical Practice, 2018
Charles Adler, Alberto Espay, Caroline Tanner   +2 more
exaly  

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

CNS Drugs, 2018
CARLOS Singer, Susan Criswell, Reed Johnson   +2 more
exaly  

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study

Journal of Parkinson's Disease, 2017
Caroline Tanner, , Rajesh Pahwa
exaly  

THE RECENT STAR FORMATION HISTORY OF NGC 5102

Astronomical Journal, 2010
Kenneth Freeman, Sebastian L Hidalgo, Colin Norman   +2 more
exaly